Education
About Us
Working with TipRanks
Follow Us
Celldex Therapeutics Inc (CLDX)
NASDAQ:CLDX
CLDX Analyst Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CLDX Stock 12 Month Forecast
Average Price Target
$52.38
▲(140.83% Upside)
| Highest Price Target$67.00 | Average Price Target$52.38 | Lowest Price Target$38.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$61
Buy
180.46%
Upside
Reiterated
08/23/25
TR | OpenAI - 4o
$25→$20.5
Hold
-5.75%
Downside
Reiterated
08/21/25
Cantor Fitzgerald
$67
Buy
208.05%
Upside
Reiterated
08/20/25
TD Cowen
―
Buy
―
Reiterated
08/20/25
Wells Fargo
$44→$38
Buy
74.71%
Upside
Reiterated
08/20/25
Citi
$56→$48
Buy
120.69%
Upside
Reiterated
08/20/25
Stifel Nicolaus
$58
Buy
166.67%
Upside
Reiterated
08/20/25
H.C. Wainwright
$50→$42
Buy
93.10%
Upside
Reiterated
08/20/25
Leerink Partners
―
Buy
―
Reiterated
08/19/25
Celldex's Barzolvolimab: Promising Safety Profile Supports Buy Rating Despite EoE Trial SetbackWe also believe barzo’s safety profile in EoE incrementally boosts confidence in the drug's safety/tolerability with CLDX’s ongoing Phase 3 EMBARQ program in CSU, where the company is utilizing loading doses (300mg & 450mg). Overall, while CLDX shares traded down after mkt (~10-20%) we believe this weakness is overdone, as we (and most investors we've spoken with) modeled no explicit value for barzo’s potential in EoE, given the lack of prior proof-of-concept data and complex pathophysiology of this disease that has led to many historical failures.
Canaccord Genuity
$64→$62
Buy
185.06%
Upside
Reiterated
08/19/25
Morgan Stanley
$43
Buy
97.70%
Upside
Reiterated
08/18/25
UBS
$44→$38
Buy
74.71%
Upside
Reiterated
05/09/25
Goldman Sachs
$42→$36
Hold
65.52%
Upside
Reiterated
02/28/25
Guggenheim
$90
Buy
313.79%
Upside
Reiterated
01/08/25
Wolfe Research
$51
Hold
134.48%
Upside
Downgraded
09/26/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$61
Buy
180.46%
Upside
Reiterated
08/23/25
TR | OpenAI - 4o
$25→$20.5
Hold
-5.75%
Downside
Reiterated
08/21/25
Cantor Fitzgerald
$67
Buy
208.05%
Upside
Reiterated
08/20/25
TD Cowen
―
Buy
―
Reiterated
08/20/25
Wells Fargo
$44→$38
Buy
74.71%
Upside
Reiterated
08/20/25
Citi
$56→$48
Buy
120.69%
Upside
Reiterated
08/20/25
Stifel Nicolaus
$58
Buy
166.67%
Upside
Reiterated
08/20/25
H.C. Wainwright
$50→$42
Buy
93.10%
Upside
Reiterated
08/20/25
Leerink Partners
―
Buy
―
Reiterated
08/19/25
Celldex's Barzolvolimab: Promising Safety Profile Supports Buy Rating Despite EoE Trial SetbackWe also believe barzo’s safety profile in EoE incrementally boosts confidence in the drug's safety/tolerability with CLDX’s ongoing Phase 3 EMBARQ program in CSU, where the company is utilizing loading doses (300mg & 450mg). Overall, while CLDX shares traded down after mkt (~10-20%) we believe this weakness is overdone, as we (and most investors we've spoken with) modeled no explicit value for barzo’s potential in EoE, given the lack of prior proof-of-concept data and complex pathophysiology of this disease that has led to many historical failures.
Canaccord Genuity
$64→$62
Buy
185.06%
Upside
Reiterated
08/19/25
Morgan Stanley
$43
Buy
97.70%
Upside
Reiterated
08/18/25
UBS
$44→$38
Buy
74.71%
Upside
Reiterated
05/09/25
Goldman Sachs
$42→$36
Hold
65.52%
Upside
Reiterated
02/28/25
Guggenheim
$90
Buy
313.79%
Upside
Reiterated
01/08/25
Wolfe Research
$51
Hold
134.48%
Upside
Downgraded
09/26/24
Best Analysts Covering Celldex
1 Month
xxx
Success Rate
15/25 ratings generated profit
Average Return
+6.40%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +6.40% per trade.
3 Months
xxx
Success Rate
14/25 ratings generated profit
Average Return
+11.48%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.00% of your transactions generating a profit, with an average return of +11.48% per trade.
1 Year
Success Rate
11/18 ratings generated profit
Average Return
+75.02%
reiterated a buy rating 8 days ago
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +75.02% per trade.
2 Years
xxx
Success Rate
9/18 ratings generated profit
Average Return
+54.06%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +54.06% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CLDX Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
6
12
16
15
21
Buy
2
1
3
3
5
Hold
1
8
10
14
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
21
29
32
37
Each month's total comprises the sum of three months' worth of ratings.
CLDX Financial Forecast
CLDX Stock Forecast FAQ
What is CLDX’s average 12-month price target, according to analysts?
Based on analyst ratings, Celldex Therapeutics Inc’s 12-month average price target is 52.38.
What is CLDX’s upside potential, based on the analysts’ average price target?
Celldex Therapeutics Inc has 140.83% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CLDX a Buy, Sell or Hold?
Celldex Therapeutics Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Celldex Therapeutics Inc’s price target?
The average price target for Celldex Therapeutics Inc is 52.38. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $67.00 ,the lowest forecast is $38.00. The average price target represents 140.83% Increase from the current price of $21.75.
The highest analyst price target is $67.00 ,the lowest forecast is $38.00. The average price target represents 140.83% Increase from the current price of $21.75.
What do analysts say about Celldex Therapeutics Inc?
Celldex Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of CLDX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.